Clinical trials
Observational Respiratory Insufficiency trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
31 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2011 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 6 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 2 |
| 2025 | 4 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 16 |
| Unknown status | 6 |
| Active, not recruiting | 4 |
| Recruiting | 3 |
| Not yet recruiting | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hospital Universitari Vall d'Hebron Research Institute | 3 |
| Hospital Universitario de Gran Canaria Doctor Negrín | 3 |
| Corporacion Parc Tauli | 2 |
| Hospital del Mar Research Institute (IMIM) | 2 |
| Jesus Villar | 2 |
| Medipol University | 2 |
| Air Liquide Healthcare Spain | 1 |
| Centro de Emergencias Sanitarias 061 Andalucía | 1 |
| Complejo Hospitalario Universitario de Albacete | 1 |
| Consorci Sanitari Integral | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Respiratory Insufficiency | 31 |
| COVID-19 | 7 |
| Respiratory Distress Syndrome | 3 |
| Acute Lung Injury | 2 |
| Coronavirus Infections | 2 |
| Pneumonia | 2 |
| Respiratory Aspiration | 2 |
| Sepsis | 2 |
| Bronchial Spasm | 1 |
| Chest Pain | 1 |
Trials
Showing 1 to 25 of 31. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.